Dr. Reddy's inks distribution deal in India with AstraZeneca subsidiary for diabetes meds

• Dr. Reddy's Laboratories (RDY -1.3%) and AstraZeneca Pharma India Limited enter a distribution agreement for a new brand of saxagliptin (AstraZeneca's (AZN -1.1%) Onglyza) called Riax and a fixed-dose combination of saxagliptin with metformin called Riax-M under which Dr. Reddy's will distribute the products in India, home to over 65M diabetics.
• Separately, Dr. Reddy's announces the launch in India of Somazina (citicoline) for the treatment of stroke patients pursuant to its agreement with Spain's Ferrer International S.A.